Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
MURDOCK COPD Observational Study: The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort
This is an observational study examining outcomes and treatment patterns in a community-based cohort of subjects with Chronic obstructive pulmonary disease (COPD) who are based in the Kannapolis, NC area.
This study is designed to collect information on the current level of symptoms and ability to
breathe, treatment and outcomes of patients with 1) Chronic Obstructive Pulmonary Disease
(COPD), or 2) in current or former smokers with respiratory symptoms but preserved pulmonary
function or 3) in current or former smokers with respiratory symptoms and preserved ratio
with impaired spirometry. This information will be used by the researchers to better
understand the impact of COPD on patients. It will also help the researchers study the
current recommendations for treatment of COPD.
Chronic obstructive pulmonary disease (COPD) represents a growing public health problem and
is now the third leading cause of death in the United States. The risk of exacerbations,
hospitalizations and death in patients with COPD tends to increase with increasing severity
of airflow limitation. However, the correlation between forced expiratory volume in 1 second
(FEV1), symptoms, and health-related quality of life is weak. The shortcomings of using
airflow limitation alone to assess the clinical severity of COPD led the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) committee to develop a potentially more
clinically meaningful approach to assess the impact of COPD on the patient. The GOLD
committee has subsequently proposed a model for pharmacologic therapy of patients with stable
COPD (i.e. those not currently experiencing a COPD exacerbation) according to GOLD risk
group. The therapeutic recommendations proposed by GOLD are widely cited as a strategy for
selecting therapy even though this model is predominantly based on expert opinion.
This study will acquire data in a community-based cohort in which patients with COPD or
current or former smokers with respiratory symptoms will be classified into GOLD risk groups
A-D at enrollment and followed longitudinally. This study will assess the frequency of change
in GOLD risk group during 5 years of follow-up, look at the use of COPD medications this
cohort and how provider-selected therapy for COPD compares to GOLD-recommended pharmacologic
therapy thus addressing a critical knowledge gap in the scientific community.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
| Active, not recruiting |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
| Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
| Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
| Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
| Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
| Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
| Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
| Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
| Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
| Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
| Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
| Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
| Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
| Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 | |
| Terminated |
NCT01388920 -
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
|
Phase 2 |